ABSTRACT Human serum albumin (HSA) is a potent inhibitor of Ab self-association and this novel, to our knowledge, function of HSA is of potential therapeutic interest for the treatment of Alzheimer's disease. It is known that HSA interacts with Ab oligomers through binding sites evenly partitioned across the three albumin domains and with comparable affinities. However, as of this writing, no information is available on the HSA-Ab interactions beyond domain resolution. Here, we map the HSA-Ab interactions at subdomain and peptide resolution. We show that each separate subdomain of HSA domain 3 inhibits Ab selfassociation. We also show that fatty acids (FAs) compete with Ab oligomers for binding to domain 3, but the determinant of the HSA/Ab oligomer interactions are markedly distinct from those of FAs. Although salt bridges with the FA carboxylate determine the FA binding affinities, hydrophobic contacts are pivotal for Ab oligomer recognition. Specifically, we identified a site of Ab oligomer recognition that spans the HSA (494-515) region and aligns with the central hydrophobic core of Ab. The HSA (495-515) segment includes residues affected by FA binding and this segment is prone to self-associate into b-amyloids, suggesting that sites involved in fibrilization may provide a lead to develop inhibitors of Ab self-association.
INTRODUCTION
Late-onset Alzheimer's disease is associated with impairment in the clearance of the amyloid beta (Ab) peptide (1) (2) (3) (4) (5) (6) (7) (8) . The Ab peptide clearance from the brain relies on the Ab transport through the blood-brain barrier promoted by agents that do not penetrate the blood-brain barrier, but bind Ab in plasma. Such agents drive an equilibrium shift of Ab from the brain toward the periphery, as posited by the peripheral-sink hypothesis (9) . Because~90% of circulating plasma Ab is bound to human serum albumin (HSA), HSA is a key mediator of Ab clearance. The pivotal role of albumin in Ab clearance is also confirmed by recent clinical investigations showing that low concentrations of albumin in plasma are associated with cognitive impairment (10, 11) . Moreover, albumin replacement through plasma dialysis has been proposed as a promising strategy for the treatment of mild Alzheimer's disease (12) . Given the physiological and potential therapeutic relevance of the Ab-albumin interactions, the stoichiometry and affinity of the Ab-albumin complexes have been recently investigated (13) . These investigations have revealed that albumin selectively targets Ab oligomers (denoted here as Ab n ) rather than Ab monomers (denoted here as Ab 1 ) (13) . The Ab oligomers are recognized by albumin through largely independent binding sites evenly partitioned across the three albumin domains (Fig. 1 a) and with comparable dissociation constants in the sub-mM range (13) . Such degeneracy in the Ab binding sites within albumin implies that each single albumin domain can be used as a model system to further probe the HSA/Ab interactions. However, the binding sites for the Ab oligomers within HSA have not been mapped beyond domain resolution, due to experimental challenges arising from the transient nature and the high molecular weight (MW) of the Ab oligomers interacting with HSA.
Here, we show how the interactions of domain 3 of HSA with Ab oligomers can be mapped at subdomain and peptide resolution. We specifically focus on domain 3 (i.e., HSA 381-585), because it remains well structured and soluble even when in isolation (13, 14) . In addition, domain 3 includes high-affinity fatty-acid (FA) binding sites and therefore it is a suitable construct to explore the competition between Ab oligomers and FAs, such as myristic acid (MA). Because the binding of MA to domain 3 has been structurally well characterized ( Fig. 1 b) (15) (16) (17) (18) (19) , the MA-versus-Ab competition is an effective approach to start mapping the Ab/ domain-3 interactions. However, given the presence of multiple MA binding sites and the possibility of indirect allosteric effects, competitive binding and inhibition experiments alone are not sufficient to narrow down the Ab binding sites within domain 3. We therefore complement the FAversus-Ab competition experiments with comparative mutational analyses. Mutants include subdomain deletions (i.e., subdomains 3A and 3B) and point mutations within each subdomain at sites of FA binding. The combination of comparative mutational analyses and competition experiments monitored by NMR provides a viable experimental strategy to effectively circumvent the challenges in mapping interactions with large and transient Ab oligomers.
Our results show that FAs compete with Ab oligomer for binding to domain 3 of HSA and that, similarly to FAs, Ab oligomers interact with both subdomains 3A and 3B, although not all the residues critical to bind FA interact with the Ab oligomers. In addition, we took our reductionist approach one step further and we identified, using a combination of bioinformatics and fluorescence, a contiguous putative Ab interaction site in subdomain 3B. The subdomain-3B peptide spanning the identified Ab interaction site was synthesized and tested for self-association inhibitory potency. The selected domain-3 peptide inhibits Ab self-association and interestingly matches well with a region of albumin prone to amyloid fibril formation. These results suggest the intriguing hypothesis that a subset of the putative sites of Ab-binding proteins involved in intermolecular contacts during protein self-association may also serve as possible Ab recognition and inhibition sites.
MATERIALS AND METHODS

Ab (12-28) peptide sample preparation
The Ab (12-28) peptide used in this investigation was purchased from Pepnome (Zhuhai City, China) with a purity of 98%. Lyophilized peptide was dissolved in 50-mM acetate buffer-d 4 at pH 4.7, with 10% D 2 O to a concentration of 1 mM. After the peptide was dissolved, the solution was filtered through an Ultrafree-MC filter (Millipore, Billerica, MA) with a 30-kDa cutoff in 5-min intervals at 3000 rpm to remove aggregates formed during the peptide lyophilization and dissolution processes (13, (20) (21) (22) . To induce aggregation a 1-M NaCl solution prepared in 50-mM acetate buffer at pH 4.7 was then added to the filtered peptide sample up to a final concentration of 40-mM NaCl, followed by a seven-day incubation period at room temperature (13, 21) .
Ab (1-42) peptide sample preparation
The Alzheimer's peptide Ab (1-42) was purchased from EZBiolab (Carmel, IN) with a purity >95%. A stock Ab (1-42) solution was prepared by dissolving 5 mg of the Ab (1-42) peptide in 2.5 mL of 10 mM NaOH (13, 22) . This stock solution was sonicated twice using 2-min intervals followed by 2-min incubation on ice. Immediately after sonication, the stock Ab (1-42) solution was divided into 100-mL aliquots and frozen at À20 C. A quantity of 100 mL of the Ab (1-42) stock solution was thawed and sonicated twice for 2 min with 2-min incubation on ice in-between before each experiment. A quantity of 450 mL of wild-type domain 3, domain 3 bound to myristic acid, and domain-3 mutant proteins in 20-mM sodium phosphate buffer at pH 7.4 was added to the sonicated peptides for collection of NMR spectra at 700 MHz with a TCI CyroProbe (Bruker BioSpin, Billerica, MA) and at 37 C. During the time between NMR data acquisition sessions, the NMR samples were stored in a water bath at 37 C and were not stirred or mixed.
Trifluoroacetic acid removal from the Ab samples
Although all peptides were commercially obtained with >95% purity, they all contained residual trifluoroacetic acid, which is routinely used in the final stage of peptide purification. To avoid potential biases, trifluoroacetic acid was removed from the Ab samples before the addition of the domain 3 using at least three lyophilization steps in the presence of 50-100 mM HCl (23) .
Preparation of human serum albumin peptides
Human serum albumin (HSA) peptides, HSA (495-515), HSA (495-515) reversed, and HSA (530-550) were purchased from GenScript USA (Piscataway, NJ) as a dry powder with purity >95%. A quantity of 0.5-mM peptides stock solutions was prepared by dissolving the lyophilized powder in water and adding 50 mM NaOH until the peptides were fully solubilized. Peptides concentration was determined by measuring their UV absorbance at 280 nm using 1490 M À1 cm À1 as extinction coefficient.
Preparation of myristic-acid stock
Myristic acid (MA) dry powder (Sigma 490873; Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO-d 6 at 100 mM. Afterwards aliquots of myristic acid were diluted to 1.5 mM in 20 mM sodium phosphate, pH 7.4 at 70 C. The stock was then cooled to 55 C and stored at that temperature for use in subsequent experiments. The myristic acid concentration was confirmed based on the comparison of the methyl signal intensity of the myristic acid 1 H-NMR spectra to the methyl intensity of an octanoic acid internal standard (Sigma 153753; Sigma-Aldrich). Protein subcloning, expression, and purification
The domain-3 gene flanked by the NdeI restriction enzyme site and six histidines at the N-terminus was generated in the pet15B vector, as previously published in Milojevic and Melacini (13) . The Y411AR410A, R485AS489A, and K525A mutants were generated following standard PCR protocols. The 3A subdomain was generated by mutating T496 into a stop codon using as a primer
The 3B construct was generated by mutating D494 and E495 into an NdeI restriction enzyme site. This was accomplished using the primer
Because the 3A subdomain was flanked by the NdeI site, digestion of this mutated DNA resulted in the excision of the 3A subdomain from the domain-3 sequence. Subsequent ligation generated a 3B subdomain DNA construct. The sequence of each constructs was confirmed through PCR-based sequencing. All proteins samples were expressed and purified as previously described in the literature (13, 14) . (13) , and therefore will not be further discussed here. The titration curves were fitted using a Scatchard-like model as previously explained (13) . Due to the transient nature of the oligomers formed by the longer Ab (1-42) peptide, the STD experiments were not performed for this longer peptide; however, the intensities of one-dimensional Watergate experiments are effective in probing aggregation of Ab (1-42) (13, 22) . These experiments rely on the incorporation of a 30-ms-long spin-lock pulse before acquisition to suppress contributions from residual protein and selectively observe the monomeric and low MW Ab signals. All experiments were acquired on an Avance 700 MHz spectrometer (Bruker BioSpin) equipped with a 5-mm TCI CyroProbe (Bruker BioSpin). The STD experiments were performed at 20 C, whereas one-dimensional watergate water-suppression NMR technique experiments were performed at 37 C. All spectra were processed with the program NMRPIPE (24) and analyzed with the software SPARKY (25) .
NMR spectroscopy
Thioflavin T fluorescence
Thioflavin T (ThT) fluorescence spectra were recorded using a Safire fluorescence spectrometer (Tecan/Life Technologies, Carlsbad, CA) and 96-well plates (half-area) with 155-mL sample volumes (22, 26) . The concentration of Ab (1-42) in all samples was 70 mM, whereas the concentration of inhibitory and control peptides, i.e., HSA (494-515) and HSA (594-515) reversed, respectively, was set to 120 mM. Measurements were performed in 30 mM HEPES buffer with 20 mM of the ThT dye at pH 7.4. As a control, individual ThT fluorescence spectra were collected for HSA peptides samples. These values were subtracted from the values obtained from the HSA peptides:Ab mixtures. For each sample, at least three measurements were performed and the average values are reported. The error was calculated as the standard deviation of all measurements.
Bioinformatics analysis
Secondary structure elements and local (three residues) root mean-square deviation changes were calculated through the MOLMOL software (27) using Protein Data Bank codes PDB:1AO6 and PDB:1E7G for apo and MA-bound HSA (18), respectively. The Waltz algorithm (http://waltz. switchlab.org/) was used to predict domain-3 regions prone to amyloid formation (28) . For the Waltz profile, the output with high sensitivity and pH 7 was chosen. The Waltz score was plotted against the residue number to show the residue-specific propensity of amyloid formation.
RESULTS
Myristic acid and Ab oligomers compete for binding to domain 3 of HSA
To probe the competition between MA and Ab binding, we measured the potency of HSA domain 3 in inhibiting Ab (1-42) self-association in the presence and absence of MA. For this purpose, we monitored the loss of Ab (1-42) one-dimensional NMR signal intensity versus time due to the formation of high-MW NMR-undetectable aggregates (Fig. 2 a) . In these experiments, the contributions to the NMR signal arising from HSA are effectively edited out through a spin-lock relaxation filter. This is a distinct advantage of NMR relative to other spectroscopies, such as ThT fluorescence, because the ThT fluorophore binds to HSA and therefore the addition of HSA may affect the detected fluorescence signal. In addition, the Ab (1-42) one-dimensional NMR signal intensity versus time profiles appear more reproducible than those obtained using ThT fluorescence (13, 22, 29) , thus facilitating the quantitative evaluation of self-association inhibitors through comparative analyses. Fig. 2 a shows that in the absence of HSA domain 3, the one-dimensional NMR signal of Ab (1-42) is rapidly lost over time, until a plateau is reached with the original intensity reduced by~40%. Upon addition of substoichiometric amounts of apo HSA domain 3, the NMR signal intensity of Ab (1-42) is dramatically increased both in the initial decay phase and in the final plateau region (Fig. 2 a) , clearly indicating that the isolated domain-3 functions as an effective Ab self-association inhibitor. However, when HSA domain 3 was added in the presence of excess MA, the inhibitory potency of domain 3 was significantly reduced, resulting in Ab (1-42) signal intensities that are intermediate between those of the two previous profiles (Fig. 2 a) . These variations in the one-dimensional NMR signal versus time profiles are attributable to either the competition between MA and Ab (1-42) for binding to domain 3 and/ or to potential interactions between free MA and Ab (1-42). To rule out the latter explanation, we monitored the one-dimensional NMR signal of Ab (1-42) over time in the absence and presence of 30 mM of MA and no Biophysical Journal 105(7) 1700-1709 significant differences were observed upon addition of 30 mM of MA (see Fig. S1 in the Supporting Material). This MA concentration exceeds the concentration of free MA expected under the conditions of Fig. 2 a ( (Fig. 2 b) and the HSA domain 3:MA specific binding stoichiometry is 1:3. We therefore conclude that the data of Fig. 2 b point to competition between MA and Ab (1-42) oligomers for binding to domain 3 of HSA.
The MA-versus-Ab competition emerging from Fig. 2 a suggests that at least some of the domain-3 residues affected by MA binding are also critical for Ab self-association inhibition. The residues affected by MA binding include those in direct contact with MA as well as those indirectly affected by MA through local conformational changes (see Fig. S2 ). Fig. S2 shows that the MA binding sites in domain 3 span both subdomains (i.e., 3A and 3B) and that the sites directly or indirectly affected by MA binding are scattered through domain 3. Considering the abundance and wide distribution of domain-3 sites affected by MA (see Fig. S2 ), we decided to further narrow down the location of sites critical for Ab self-association inhibition by complementing the competition experiments of Fig. 2 with comparative mutational analyses.
The first set of mutants was designed to address the question as to whether Ab binds both subdomains (i.e., 3A and 3B), similarly to MA, or it is selective for a single subdomain. For this purpose, we have subcloned, expressed, and purified separate 3A and 3B subdomain constructs and tested their interactions with two Ab peptides, Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) and Ab (1-42). The former peptide spans the central hydrophobic core of the Ab peptide as well as key residues involved in HSA binding (13, 21, 22) and was included in the analyses, because unlike Ab (1-42), it forms stable soluble Ab oligomers. Furthermore, the binding of Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) oligomers to albumin can be monitored by STD NMR experiments, resulting in albumin inhibition isotherms from which quantitative effective K D values for the Ab oligomer:HSA complexes are obtained based on Scatchard-like models, as previously explained (13) . In addition, the Ab (12-28) STD-versus-[HSA] inhibition profiles exhibit a clear plateau whose starting point provides an estimation of the effective concentration of protein (i.e., HSA) necessary to saturate the Ab (12-28) oligomers binding sites (13) .
Subdomains 3A and 3B are minimal structural units that retain potency in inhibiting Ab self-association Fig. 3 , a and b, shows the concentration-dependent STDmonitored Ab (12-28) self-association inhibition profiles measured for subdomains 3A and 3B. The STD-monitored titration data (Fig. 3, a and b) display a typical doseresponse pattern in which I STD /I STR decrease progressively as the subdomain concentration increases, until a saturation plateau is reached, indicating that both subdomains span specific Ab oligomers binding sites. These interactions are compatible with at least two different stoichiometries for the domain 3:Ab n complexes. In the first stoichiometry, a single Ab oligomer interacts with both subdomains. In this case, we expect that, in going from the integral domain 3 to the separate subdomains, the average effective number of Ab oligomers bound per molecule of albumin construct, defined as n Abn , will remain largely unaffected, although the affinity may change. In the second putative stoichiometry, two distinct Ab oligomers interact with the two subdomains. In this case, we expect that, in going from the integral domain 3 to the separate subdomains, n Abn should approximately halve. The initial (t ¼ 0) amplitude quantifies the NMR-detectable species present after the dead time of the experiment, i.e., the time interval elapsed between sample preparation and the beginning of the NMR data acquisition. The Ab (1-42) concentration of 90 mM was chosen because, under our experimental conditions, it provides an optimal compromise between the signal/noise of each sampled spectrum and the time resolution of the decay. We recognize that this concentration is higher than those typically reported for in vivo Ab (i.e., lower than nanomolar in human plasma (10)). However, our in vitro conditions allowed us to test the effect of albumin on a wide range of Ab assemblies from monomers to fibrils, increasing the likelihood to mimic also the Ab association states relevant in vivo. (b) STR and STD spectra for apo Domain 3 were subtracted from the respective spectra at each titration point.
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To discriminate between the two possible domain 3:Ab n stoichiometries discussed above, we also measured as a reference the Ab (12-28) self-association inhibition STD profile for the integral domain 3 (Fig. 3 c) . All three STD profiles of Fig. 3 , a-c, were fitted to a Scatchard-like model, which provides the gh[Ab n ] Tot i product (13) , where h[Ab n ] Tot i is the average effective total concentration of albumin-binding competent Ab oligomers. Here, g ¼ n protein /n Abn , where n protein is the average effective number of albumin protein construct molecules (i.e., domain 3 or subdomain 3A or 3B) bound per Ab oligomer, and n Abn is defined as above, i.e., the average effective number of Ab oligomers bound per molecule of albumin construct (13) . Because the measurements in Fig. 3 , a-c, were recorded utilizing the same Ab stock solution, h[Ab n ] Tot i does not change appreciably in the inhibition STD profiles of domain 3 and subdomains 3A and 3B (Fig. 3, a-c) . Similarly, n protein is not expected to vary in going from panels a-c of Fig. 3 and to be~1, as previously reported (13) . As a result, variations in the fitted gh[Ab n ] Tot i product across the three panels of Fig. 3 , a-c, report primarily on changes in n Abn , allowing us to differentiate between the two proposed putative stoichiometries for binding of Ab oligomers to domain 3 of albumin.
The comparison of the STD profile in Fig. 3 c with those in Fig. 3, a and b , clearly shows that in going from domain 3 to the either one of the two separate subdomains, gh[Ab n ] Tot i is doubled (Fig. 3, a-c) , as expected if the n Abn value of domain 3 is approximately twice the n Abn value for the isolated 3A or 3B subdomains. These observations support the second stoichiometric pattern, whereby each subdomain binds a different Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) oligomer. This conclusion is also consistent with the inhibitory potencies measured for the two subdomains using the longer Ab (1-42) peptide (Fig. 3 d) . Fig. 3 d consistently indicates that domain 3 exhibits higher inhibition potency than the individual subdomains, corroborating that both subdomains, 3A and 3B, are involved in Ab oligomer binding. Given that each subdomain interacts with Ab n , the next open question we focused on pertains to the specific Ab n contact sites within each HSA subdomain.
Comparison of Ab and fatty acid binding modes: effects of hydrogen-bonding perturbing mutations
Given the competition between fatty acids (FAs) and Ab oligomers supported by Fig. 2 , we hypothesized that Ab and FAs might share common binding determinants. To test this hypothesis, we investigated the interaction between Ab and domain-3 mutants that hamper FA binding by removing side chains involved in hydrogen bonds to the FA carboxylate. For instance, the R410A/Y411A and R485A/S489A double mutations (Fig. 4, b and d) drastically reduce fatty-acid binding to subdomain 3A (see Fig. S3 , a and b), whereas K525A (Fig. 4 f) markedly decreases FA binding to subdomain 3B (see Fig. S3 c) (17) . Therefore, we tested the interactions of these three sets of domain-3 mutants (i.e., R410A/Y411A, R485A/S489A, and K525A) with Ab oligomers. Fig. 4 , a, c, and e, reports Time (hours) Biophysical Journal 105 (7) 1700-1709
the STD-monitored titration of Ab (12-28) with the R410A/ Y411A, R485A/S489A, and K525A domain-3 mutants. The STD profiles shown in Fig. 4 , a, c, and e (black dots), indicate that all three domain-3 mutants are active inhibitors of Ab (12-28) self-association. Furthermore, no significant differences were observed when the titration profile of each mutant was compared to the corresponding profile for the wild-type domain 3 (Fig. 4, a, c , and e, red dots). These results suggest that mutations that disrupt the interactions of domain 3 with FAs (see Fig. S3 ) do not necessarily affect Ab (12-28) oligomer binding, pointing to marked differences between the HSA binding determinants for FAs and those for the Ab (12-28) oligomers. To confirm the validity of this conclusion for longer and more physiologically relevant Ab peptides, we also tested the interactions between the three domain-3 mutants and Ab (1-42).
The experiments on the Ab (1-42) peptide (Fig. 4 g ) confirmed the differences between the Ab and FA binding modes already emerged from the STD experiments on Ab (12-28) (Fig. 4, a, c, and e) . Specifically, Fig. 4 g indicates that the incubation of Ab (1-42) at 37 C results in peptide aggregation and consequent losses in the Ab NMR signal over time. These signal losses are significantly reduced in the presence of wild-type domain 3 (Fig. 4 g) . A similar reduction in aggregation is observed for all domain-3 mutants, suggesting that the mutations did not significantly perturb binding of the Ab oligomers to domain 3 (Fig. 4 g) , although they had a marked effect on FA binding (see Fig. S3 ) (17) . We conclude that the mutated residues (i.e., R410, Y411, S489, R485, and K525), although involved in hydrogen bonds with albumin-bound FAs, are not part of the HSA domain-3 determinants for Ab binding. To further dissect the domain-3 residues involved in Ab binding, we focused on subdomain 3B, because it provides a minimal structural unit that still inhibits Ab self-association (Fig. 3, a and d) and it includes only a single well-defined FA binding site.
Dissecting the subdomain-3B determinants for Ab binding
As a first step toward narrowing down the Ab binding sites within subdomain 3B, we verified that this construct retains FA binding capacity and that FA binding competes with Ab binding. Fig. S4 a shows the STD amplification factor for a titration of MA into subdomain 3B. A clear dose-response pattern with plateau is observed, confirming that MA binds specifically to our 3B construct. Furthermore, Fig. S4 b, similarly to Fig. 2 a, clearly shows that MA binding decreases the Ab self-association inhibitory potency of the 3B construct, indicating that the MA-versus-Ab oligomer competition occurs also at the level of subdomain 3B. This observation suggests that the 3B residues interacting with the Ab oligomers are either in direct contact with the FA (see Fig. S2 , open circles) and/or are indirectly affected by FA binding through conformational changes (see Fig. S2 , local root mean-square deviation).
To further screen for the 3B sites that recognize Ab oligomers, we hypothesized that, because Ab monomers and HSA compete for the same binding partner (i.e., Ab oligomers), the recognition of Ab oligomers by HSA should to some extent resemble the recognition of Ab oligomers by Ab monomers. Based on this hypothesis, HSA residues with high propensity to bind to Ab oligomers and protofibrils should meet two additional criteria: 1). They should fall in regions of HSA prone to adopt a b-strand conformation and to self-associate into amyloid fibrils. For instance, the Waltz algorithm (28) predicts that three distinct segments of subdomain 3B are likely to be involved in HSA self-association ( Fig. 5 b) , with the longest region spanning residues 494-515. 2). Sites that recognize Ab assemblies are likely to align in sequence with the Ab residues involved in self-recognition. For instance, the central hydrophobic core of Ab (i.e., L 17 VFFA 21 ) is known to be critical for Ab selfassociation and aligns well with several residues in the 494-515 segment of HSA (Fig. 5 c) . Interestingly, the 494-515 region also includes several loci of FAdependent conformational change (see Fig. S2 ). Overall, the 494-515 HSA segment emerges as a consensus sequence for Ab oligomer binding, which is consistent with the MA competition data (see Fig. S4 ) and meets the two bioinformatic criteria of amyloid propensity and Ab alignment (Fig. 5, b and c) .
Based on these observations, we hypothesized that the HSA (494-515) peptide retains Ab self-association inhibitory potency. To test this hypothesis, we measured the inhibitory potencies of the HSA (494-515) synthetic peptide using both the Ab (12-28) and Ab (1-42) systems. We also included in our measurements two negative controls, i.e., the reversed HSA (494-515) peptide, to check the specificity of the HSA peptide/Ab interactions, and the HSA (530-550) peptide, which spans a region of subdomain 3B that does not meet our two bioinformatic criteria (Fig. 5,  b and c) . (Fig. 6 a) , pointing to specific interactions between this HSA peptide and Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . The specificity of these interactions is further confirmed by the dramatically reduced affinity for Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) observed for the reversed HSA (494-515) peptide (Fig. 6 a) , which results in an effective K d approximately one order-of-magnitude higher than that Biophysical Journal 105(7) 1700-1709 measured for the wild-type HSA (494-515) counterpart (Fig. 6 a) . In addition, as expected, no Ab (12-28) selfassociation inhibition was observed for the other negative control peptide, i.e., HSA (530-550) (Fig. 6 a) , confirming the usefulness of the bioinformatic selection criteria.
The results obtained for Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (Fig. 6 a) were confirmed when the HSA peptides were tested on Ab (1-42) (Fig. 6 b) . The self-association of Ab (1-42) was not monitored by NMR intensity losses because of the overlap between the NMR signals of the Ab (1-42) and the HSA (494-515) peptides. The sharp and intense NMR lines of the flexible HSA (494-515) peptide are not easily edited out through a spin-lock relaxation filter without significant intensity losses for the Ab (1-42) peptide as well, unlike the case of larger and well-structured HSA constructs. However, unlike full-length HSA, the HSA (494-515) peptide under our experimental conditions does not affect the fluorescence of ThT in the absence of Ab (1-42) (see Fig. S5 ). We therefore resorted to ThT fluorescence to monitor the formation of cross-b amyloid assemblies (Fig. 6 b) . Fig. 6 b shows that the HSA (494-515) peptide significantly reduces the ThT fluorescence arising from the Ab (1-42) cross-b amyloids formed during a 15-h incubation period. This inhibitory effect is completely lost when the HSA (494-515) sequence is reversed (Fig. 6 b) . Overall, the data for Ab (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) and Ab (1-42) (Fig. 6, a and b) consistently point to the HSA (494-515) region as a site of specific HSA/Ab contacts, confirming our hypothesis based on the FA competition experiments and bioinformatic analyses (Fig. 5) .
DISCUSSION
The consensus model emerging from the data presented here provides unprecedented insight about the HSA:Ab oligomer interactions well beyond the previously available domain resolution. We show that each separate subdomain of HSA domain 3 retains Ab self-association inhibitory potency and is able to bind Ab oligomers with a sub-mM affinity (Fig. 3) . The FA binding sites are also located in both subdomains 3A and 3B (Fig. 1) , and FAs compete with Ab oligomers for binding to domain 3 ( Fig. 2 and see Fig. S4 ). However, the determinant of the HSA/Ab oligomers interactions is markedly distinct from those of FAs (Fig. 4) . For FAs, although extensive hydrophobic contacts are common, it is the strength of hydrogen bonds/salt bridges formed between the albumin amino-acid side chains and the fatty acid carboxylate groups that determine the binding affinities (see Fig. S3 ) (15, 16) . For Ab, the relevance of these specific polar/ionic interactions becomes marginal (Fig. 4) , but hydrophobic contacts appear to play a pivotal role for Ab oligomer recognition (Figs. 5 and 6 ). For instance, in the case of subdomain 3B, a site of Ab oligomer recognition spans the HSA (494-515) region, which includes hydrophobic sites in contact with the aliphatic tail of MA and subject to changes in conformation upon FA binding (see Fig. S2 ). The (494-515) HSA region thus explains the competition between FA and Ab oligomer for binding to HSA subdomain 3B, although at this stage we cannot rule out that other HSA sites may also contribute to the observed FA-versus-Ab n competition. Interestingly, the (494-515) segment also includes several residues that align to the central hydrophobic core sequence of Ab (i.e.,L 17 -VFFA 21 , Fig. 5 c) .
The importance of the hydrophobic effect in the binding of Ab oligomers is supported by the observation that several other Ab binding proteins, such as sLRP (30) , clusterin (31, 32) , and ApoE (33) , are also involved in lipid binding. Additionally, it was recently shown that binding of Ab to proteins not involved in lipid metabolism, such as ABAD and affibody Z Ab3 , is accompanied by a favorable entropic change, consistent with hydrophobically driven protein:Ab interactions (34) (35) (36) . Furthermore, the solution structure of the complex between Ab and the affibody Z Ab3 dimer revealed a large hydrophobic cavity, which is required for high Ab affinity (36) .
The observations that the HSA (494-515) peptide inhibits Ab self-association (Fig. 6 ) and is also prone to self-association into cross-b fibrils (Fig. 5 b) suggest the hypothesis that protein segments prone to b-strand formation and self-association into amyloid deposits may also serve as sites that target Ab oligomers at their growing loci, where Ab monomers would otherwise bind. This notion is supported by the structure of the affibody Z Ab3 bound to Ab, revealing that the Ab peptide interacts with a b-strand of Z Ab3 (36) . Overall, the criteria of hydrophobicity, b-strand propensity, and involvement in protein:protein self-association emerging from our investigation of albumin:Ab n interactions will facilitate the initial screening for peptide regions that may serve as potential inhibitors of Ab fibrilization. In addition, we anticipate that the methods and experimental approaches utilized here to map the albumin:Ab n interactions will be at least in part transferable to other amyloid inhibitory systems (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . Figure S2 . Three residue average local backbone RMSDs computed for domain 3 using the structures of HSA in the apo and myristic acid-bound forms (PDB codes 1AO6 and 1E7G, respectively). Secondary structure elements of domain 3 are shown in the upper area, while residues in direct contact with myristic acid are indicated using circles and dotted red lines. Local RMSDs were calculated using MOLMOL (27) , while contact residues were extracted from the PDB files using Ligand Explorer Software (39) . The black dotted vertical line indicates the sub-domain 3A / 3B boundary, while residues highlighted in grey indicate the HSA derived peptides used in this study ( Figures 5 and  6 ). showing that this peptide does not form cross-β amyloid fibrils under our experimental conditions. These conditions differ markedly from those used in the original Waltz protocol (28) in which higher concentrations of peptide and buffer (500 mM phosphate buffer) were employed, explaining why under our experimental conditions no cross-β amyloid fibrils were observed for HSA (494-515). The ThT fluorescence of 90 µM Aβ (1-42) alone ( Figure 6 ) is reported here as well (white circles) for the convenience of comparison. Figure S1 
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